Diabetic cardiomyopathy: Mechanisms and therapeutic targets

Drug Discovery Today: Disease Mechanisms

Volumn 7, Issue 2, 2010, Pages

  Battiprolu, Pavan K ^a   Gillette, Thomas G ^a   Wang, Zhao V ^a   Lavandero, Sergio ^a,b   Hill, Joseph A ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b UNIVERSITY OF CHILE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; AMIODARONE; METFORMIN; PERHEXILINE; RANOLAZINE; RESVERATROL; TRANSCRIPTION FACTOR FOXO; TRIMETAZIDINE;

CALCIUM CELL LEVEL; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DRUG TARGETING; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERLIPIDEMIA; INSULIN RESISTANCE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; REVIEW;

EID: 78649326868     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2010.08.001     Document Type: Review

References (85)

1. Lloyd-Jones, D. et al. Executive summary: heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation 121, 948-954
2. H. King Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections Diabetes Care 21 1998 1414 1431
3. W.B. Kannel Role of diabetes in congestive heart failure: the Framingham study Am. J. Cardiol. 34 1974 29 34
4. N. Sarwar Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies Lancet 375 2010 2215 2222
5. S. Rubler New type of cardiomyopathy associated with diabetic glomerulosclerosis Am. J. Cardiol. 30 1972 595 602
6. J.K. Boyer Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus Am. J. Cardiol. 93 2004 870 875
7. D. An, and B. Rodrigues Role of changes in cardiac metabolism in development of diabetic cardiomyopathy Am. J. Physiol. Heart Circ. Physiol. 291 2006 H1489 H1506
8. S. Boudina, and E.D. Abel Diabetic cardiomyopathy, causes and effects Rev. Endocr. Metab. Disord. 11 2010 31 39
9. J.S. Dobrin, and D. Lebeche Diabetic cardiomyopathy: signaling defects and therapeutic approaches Expert Rev. Cardiovasc. Ther. 8 2010 373 391
10. Z.Y. Fang Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications Endocr. Rev. 25 2004 543 567
11. S.A. Hayat Diabetic cardiomyopathy: mechanisms, diagnosis and treatment Clin. Sci. (Lond) 107 2004 539 557
12. M. Stumvoll Type 2 diabetes: principles of pathogenesis and therapy Lancet 365 2005 1333 1346
13. M.F. White Insulin signaling in health and disease Science 302 2003 1710 1711
14. C. Weyer The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus J. Clin. Invest. 104 1999 787 794
15. C. Meyer Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus J. Clin. Invest. 102 1998 619 624
16. I.G. Poornima Diabetic cardiomyopathy: the search for a unifying hypothesis Circ. Res. 98 2006 596 605
17. M. Brownlee Biochemistry and molecular cell biology of diabetic complications Nature 414 2001 813 820
18. L. Cai Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway Diabetes 51 2002 1938 1948
19. M.J. Eliasson Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia Nat. Med. 3 1997 1089 1095
20. M. Montagnani Diabetic cardiomyopathy: how much does it depend on AGE? Br. J. Pharmacol. 154 2008 725 726
21. A.S. Galvez Aldose reductase induced by hyperosmotic stress mediates cardiomyocyte apoptosis: differential effects of sorbitol and mannitol J. Biol. Chem. 278 2003 38484 38494
22. J.J. Luiken Insulin stimulates long-chain fatty acid utilization by rat cardiac myocytes through cellular redistribution of FAT/CD36 Diabetes 51 2002 3113 3119
23. Wende, A.R. and Abel, E.D. Lipotoxicity in the heart. Biochim. Biophys. Acta 1801, 311-319
24. M. Khullar Oxidative stress: a key contributor to diabetic cardiomyopathy Can. J. Physiol. Pharmacol. 88 2010 233 240
25. J.G. Leichman The metabolic syndrome and the heart - a considered opinion Clin. Res. Cardiol. 95 Suppl. 1 2006 pi134 pi141
26. G.D. Lopaschuk Metabolic abnormalities in the diabetic heart Heart Fail Rev. 7 2002 149 159
27. T.S. Park Ceramide is a cardiotoxin in lipotoxic cardiomyopathy J. Lipid Res. 49 2008 2101 2112
28. L.Y. Zhang Role of fatty acid uptake and fatty acid beta-oxidation in mediating insulin resistance in heart and skeletal muscle Biochim. Biophys. Acta - Mol. Cell Biol. Lipids 1801 2010 1 22
29. G.X. Liu Long-chain acyl-coenzyme A esters and fatty acids directly link metabolism to K-ATP channels in the heart Circ. Res. 88 2001 918 924
30. G. Iacobellis Relationship of insulin sensitivity and left ventricular mass in uncomplicated obesity Obes. Res. 11 2003 518 524
31. A. Ilercil Associations of insulin levels with left ventricular structure and function in American Indians - The Strong Heart Study Diabetes 51 2002 1543 1547
32. J. Heineke, and J.D. Molkentin Regulation of cardiac hypertrophy by intracellular signalling pathways Nat. Rev. Mol. Cell Biol. 7 2006 589 600
33. J.R. Privratsky AT1 blockade prevents glucose-induced cardiac dysfunction in ventricular myocytes: role of the AT1 receptor and NADPH oxidase Hypertension 42 2003 206 212
34. C. Morisco Akt mediates the cross-talk between beta-adrenergic and insulin receptors in neonatal cardiomyocytes Circ. Res. 96 2005 180 188
35. A.M. Samuelsson Hyperinsulinemia: effect on cardiac mass/function, angiotensin II receptor expression, and insulin signaling pathways Am. J. Physiol. Heart Circ. Physiol. 291 2006 H787 H796
36. B. Rodrigues Metabolic disturbances in diabetic cardiomyopathy Mol. Cell Biochem. 180 1998 53 57
37. M. Ueno Regulation of insulin signalling by hyperinsulinaemia: role of IRS-1/2 serine phosphorylation and the mTOR/p70 S6K pathway Diabetologia 48 2005 506 518
38. E.D. Abel Insulin signaling in heart muscle: lessons from genetically engineered mouse models Curr. Hypertens. Rep. 6 2004 416 423
39. M.J. Berridge Calcium signalling: dynamics, homeostasis and remodelling Nat. Rev. Mol. Cell Biol. 4 2003 517 529
40. D.D. Belke Decreased sarcoplasmic reticulum activity and contractility in diabetic db/db mouse heart Diabetes 53 2004 3201 3208
41. L. Golfman Cardiac sarcolemmal Na(+)-Ca2+ exchange and Na(+)-K+ ATPase activities and gene expression in alloxan-induced diabetes in rats Mol. Cell Biochem. 188 1998 91 101
42. Y. Hattori Diminished function and expression of the cardiac Na+-Ca2+ exchanger in diabetic rats: implication in Ca2+ overload J. Physiol. 527 Pt 1 2000 85 94
43. L. Pereira Mechanisms of [Ca2+]i transient decrease in cardiomyopathy of db/db type 2 diabetic mice Diabetes 55 2006 608 615
44. S.U. Trost Overexpression of the sarcoplasmic reticulum Ca(2+)-ATPase improves myocardial contractility in diabetic cardiomyopathy Diabetes 51 2002 1166 1171
45. E. Shen Rac1 is required for cardiomyocyte apoptosis during hyperglycemia Diabetes 58 2009 2386 2395
46. J. Li Deficiency of Rac1 blocks NADPH oxidase activation, inhibits endoplasmic reticulum stress and reduces myocardial remodeling in type-I diabetic mice Diabetes 2010
47. S. Boudina, and E.D. Abel Diabetic cardiomyopathy revisited Circulation 115 2007 3213 3223
48. F. Fyhrquist, and O. Saijonmaa Renin-angiotensin system revisited J. Intern. Med. 264 2008 224 236
49. J.A. Olivares-Reyes Angiotensin II and the development of insulin resistance: implications for diabetes Mol. Cell Endocrinol. 302 2009 128 139
50. D.E. Dostal The cardiac renin-angiotensin system: novel signaling mechanisms related to cardiac growth and function Regul. Pept. 91 2000 1 11
51. A. Modesti Hyperglycemia activates JAK2 signaling pathway in human failing myocytes via angiotensin II-mediated oxidative stress Diabetes 54 2005 394 401
52. S. Neumann Aldosterone and d-glucose stimulate the proliferation of human cardiac myofibroblasts in vitro Hypertension 39 2002 756 760
53. N.S. Dhalla Subcellular remodeling and heart dysfunction in chronic diabetes Cardiovasc. Res. 40 1998 239 247
54. A. Frustaci Myocardial cell death in human diabetes Circ. Res. 87 2000 1123 1132
55. R. Yang, and L.A. Barouch Leptin signaling and obesity: cardiovascular consequences Circ. Res. 101 2007 545 559
56. K.R. McGaffin Leptin signalling reduces the severity of cardiac dysfunction and remodelling after chronic ischaemic injury Cardiovasc. Res. 77 2008 54 63
57. C.C. Smith Leptin, the obesity-associated hormone, exhibits direct cardioprotective effects Br. J. Pharmacol. 149 2006 5 13
58. P.E. Scherer Adipose tissue: from lipid storage compartment to endocrine organ Diabetes 55 2006 1537 1545
59. T. Kadowaki Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome J. Clin. Invest. 116 2006 1784 1792
60. Z.V. Wang, and P.E. Scherer Adiponectin, cardiovascular function, and hypertension Hypertension 51 2008 8 14
61. R. Shibata Adiponectin-mediated modulation of hypertrophic signals in the heart Nat. Med. 10 2004 1384 1389
62. R. Shibata Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms Nat. Med. 11 2005 1096 1103
63. G. Ding Adiponectin and its receptors are expressed in adult ventricular cardiomyocytes and upregulated by activation of peroxisome proliferator- activated receptor gamma J. Mol. Cell Cardiol. 43 2007 73 84
64. M. Iwabu Adiponectin and AdipoR1 regulate PGC-1alpha and mitochondria by Ca(2+) and AMPK/SIRT1 Nature 464 2010 1313 1319
65. S.D. Patel Disulfide-dependent multimeric assembly of resistin family hormones Science 304 2004 1154 1158
66. M.A. Lazar Resistin- and obesity-associated metabolic diseases Horm. Metab. Res. 39 2007 710 716
67. D.S. Frankel Resistin, adiponectin, and risk of heart failure the Framingham offspring study J. Am. Coll. Cardiol. 53 2009 754 762
68. M. Kim Role of resistin in cardiac contractility and hypertrophy J. Mol. Cell. Cardiol. 45 2008 270 280
69. A. Ferdous FoxO, autophagy, and cardiac remodeling J. Cardiovasc. Transl. Res. 3 2010 355 364
70. S.M. Ronnebaum, and C. Patterson The FoxO family in cardiac function and dysfunction Annu. Rev. Physiol. 72 2010 81 94
71. C. Skurk The FOXO3a transcription factor regulates cardiac myocyte size downstream of AKT signaling J. Biol. Chem. 280 2005 20814 20823
72. Y.G. Ni Foxo transcription factors blunt cardiac hypertrophy by inhibiting calcineurin signaling Circulation 114 2006 1159 1168
73. A. Sengupta FoxO transcription factors promote autophagy in cardiomyocytes J. Biol. Chem. 284 2009 28319 28331
74. M. Stahl The forkhead transcription factor FoxO regulates transcription of p27Kip1 and Bim in response to IL-2 J. Immunol. 168 2002 5024 5031
75. G.J. Kops Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress Nature 419 2002 316 321
76. P. Puigserver Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction Nature 423 2003 550 555
77. R.H. Medema AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1 Nature 404 2000 782 787
78. S. Ogg The Fork head transcription factor DAF-16 transduces insulin-like metabolic and longevity signals in C. elegans Nature 389 1997 994 999
79. Y.G. Ni FoxO transcription factors activate Akt and attenuate insulin signaling in heart by inhibiting protein phosphatases Proc. Natl. Acad. Sci. U. S. A. 104 2007 20517 20522
80. W.C. Knowler 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study Lancet 374 2009 1677 1686
81. A.S. Kim AMP-activated protein kinase: a core signalling pathway in the heart Acta Physiol. (Oxf) 196 2009 37 53
82. V.A. Fonseca Confronting the type 2 diabetes epidemic: the emerging role of incretin-based therapies Am. J. Med. 123 2010 S2 S10
83. J.D. Horowitz Modulation of myocardial metabolism: an emerging therapeutic principle Curr. Opin. Cardiol. 25 2010 329 334
84. S. Sharma Antidiabetic activity of resveratrol, a known SIRT1 activator in a genetic model for type-2 diabetes Phytother. Res. 2010
85. T. Finkel Recent progress in the biology and physiology of sirtuins Nature 460 2009 587 591